Rivastigmine Patch 9.5 cm2
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Parkinsons Disease With Dementia
Conditions
Parkinsons Disease With Dementia, Parkinsons Disease With Mild to Moderate Memory and/or Thinking Problems
Trial Timeline
Apr 1, 2010 → Apr 1, 2011
NCT ID
NCT00988117About Rivastigmine Patch 9.5 cm2
Rivastigmine Patch 9.5 cm2 is a approved stage product being developed by Novartis for Parkinsons Disease With Dementia. The current trial status is completed. This product is registered under clinical trial identifier NCT00988117. Target conditions include Parkinsons Disease With Dementia, Parkinsons Disease With Mild to Moderate Memory and/or Thinking Problems.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00988117 | Approved | Completed |
Competing Products
5 competing products in Parkinsons Disease With Dementia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Mirabegron + Placebo | Astellas Pharma | Approved | 85 |
| Prasinezumab + Placebo | Roche | Phase 2 | 52 |
| ALN-SNCA + Placebo | Regeneron Pharmaceuticals | Phase 1 | 32 |
| bemdaneprocel | Bayer | Phase 3 | 74 |
| High dose ANAVEX2-73 + Mid dose ANAVEX2-73 + Placebo oral capsule | Anavex Life Sciences | Phase 2 | 44 |